The Food and Drug Administration (FDA) has approved Tecentriq Hybreza ™ (atezolizumab and hyaluronidase-tqjs) for subcutaneous (SC) injection, for all the approved adult indications of ...

Patients with HCC treated with a combination of the immune checkpoint inhibitor atezolizumab and angiogenesis inhibitor bevacizumab after resection or ablation showed a 28% improvement in ...

The US Food and Drug Administration (FDA) has approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) as a subcutaneous injection in adults, covering all approved ...

This is also called metastatic breast cancer, advanced breast cancer, or stage 4 breast cancer Atezolizumab is a type of immunotherapy drug called a checkpoint inhibitor. It works by blocking a ...

Following on from information provided to NICE by the company, the appraisal of Atezolizumab with chemotherapy for untreated recurrent or advanced endometrial cancer [ID6417] has been discontinued.